ARA290 (Cibinetide) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.
ARA290 (Cibinetide) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.
[1] Hache G, et al. Shock. 2016 Oct;46(4):390-7.
Animal experiment: | Diabetic Goto-Kakizaki (GK) rats, originating from Wistar rats, are bred in our department. Normal Wistar (W) rats are used as nondiabetic controls. All animals are about six weeks old and with body weights 100 to 150 g when treatment is initiated. They are kept at 22°C on a reversed 12-h light-dark cycle with free access to food, except when fasted overnight as noted below. Rats are treated over 4 wks with ARA290 by a once daily subcutaneous (s.c.) injection at a dose of 30 μg/kg body weight or PBS. Blood samples for determination of glucose are taken after a small tail incision and analyzed every week before morning s.c. injection of either ARA290 or placebo. During the experimental period, body weights are measured weekly. |
参考文献: [1]. Hache G, et al. ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability. Shock. 2016 Oct;46(4):390-7 | |
动态评分
0.0